摘要
目的探讨地塞米松注射液在呼吸道感染患者中的应用效果。方法选取我院2016年5月~2018年5月收治的120例呼吸道感染患者作为研究对象,按照不同治疗方法分为治疗组(60例)与对照组(60例)。治疗组采用对症治疗联合地塞米松注射液治疗,对照组仅采用单纯对照治疗。比较两组的体温恢复情况、不良反应发生情况、生活质量SF-36评分。结果治疗组的体温恢复时间、治疗时间均短于对照组,差异有统计学意义(P<0.05);治疗组的不良反应总发生率高于对照组,差异有统计学意义(P<0.05);治疗组治疗后的生活质量SF-36评分高于对照组,差异有统计学意义(P<0.05)。结论临床对呼吸道感染患者采用地塞米松注射液治疗,虽可加速体温恢复正常,从而提高生活质量,但值得注意的是,其不良反应发生率较高,建议谨慎使用。
Objective To explore the application effect of Dexamethasone Injection in patients with respiratory tract infection.Methods A total of 120 patients with respiratory tract infection admitted to our hospital from May 2016 to May 2018 were selected as study subjects,and divided into the treatment group(60 cases) and the control group(60 cases) according to different treatment methods.Symptomatic treatment combined with Dexamethasone Injection was used in the treatment group,while the control group was only treated with simple control.Temperature recovery,adverse reactions,and quality of life SF-36 scores were compared between the two groups.Results The temperature recovery time and treatment time of the treatment group were shorter than those of the control group,and the differences were statistically significant(P<0.05).The total incidence rate of adverse reaction of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).Quality of life SF-36 score in the treatment group after treatment was higher than that in the control group,the difference was statistically significant(P<0.05).Conclusion Dexamethasone Injection can accelerate the recovery of body temperature and improve the quality of life in patients with respiratory tract infection.However,it is worth noting that the adverse reaction rate is relatively high and it is recommended to be used cautiously.
引文
[1]张璐,王玉青,赵磊,等.ICU患者下呼吸道感染病原菌与耐药性分析[J].中华医院感染学杂志,2016,26(14):3161-3163.
[2]李结嫦,吴敏,黄美婷.地塞米松磷酸钠注射液应用后常见不良反应分析[J].深圳中西医结合杂志,2016,26(6):139-140.
[3]何勇强.我院地塞米松治疗上呼吸道感染的不良反应临床观察[J].海峡药学,2013,25(2):263-265.
[4]朱美勤.地塞米松磷酸钠注射液治疗后常见不良反应表现及影响[J].临床研究,2016,24(12):228-229.
[5]Gao GF,Gao L.Incompatibility between injection hemagglutinase and dexamethasone injection[J].South Na D Med J,2014,24(12):1363.
[6]司继刚.地塞米松注射液临床应用安全性分析评价[J].中国药学杂志,2016,51(22):1972-1975.
[7]吴滨,赵荣娟.哌拉西林钠他唑巴坦钠注射剂联合地塞米松注射液治疗社区获得性肺炎伴发热的临床研究[J].中国临床药理学杂志,2017,33(4):291-293.
[8]李芸,胡国仙,周华,等.门诊老年患者呼吸道感染病原菌分布与影响因素分析[J].中华医院感染学杂志,2016,26(2):314-316.
[9]Dang Q,Zhou XG,Tong J,et al.Evaluation of C-reactive protein in early diagnosis of respiratory tract infections[J].Chin J Noso,2016,26(7):1645-1646.
[10]张春晓,王永亮,鲁广建,等.耐多药肺结核患者呼吸道感染的病原菌分布与耐药性分析[J].中华医院感染学杂志,2016,26(7):1489-1491.
[11]徐桂琴,李晗,李雪苓.清热解毒法在急性上呼吸道感染中的应用分析[J].中国中医急症,2017,26(8):1416-1417.
[12]上官斌.地塞米松注射液治疗上呼吸道感染的临床不良反应情况分析[J].中国继续医学教育,2017,9(8):164-166.
[13]邹华.急性上呼吸道感染的合理用药[J].中国实用医药,2016,26(5):232-235.
[14]李建华,张力燕,季云瑞,等.呼吸内科不同区域下呼吸道感染耐药菌分布及耐药特征比较分析[J].重庆医学,2016,45(10):1330-1333.
[15]毕永春,罗浔阳,李玉麒,等.CRP与血常规联合检测在儿科急性上呼吸道感染诊断中的应用[J].中国实验诊断学,2016,20(10):1738-1740.
[16]高菲,丁长玲,成文娜.地塞米松磷酸钠注射液致过敏1例[J].中国医院用药评价与分析,2016,16(11):1581.